{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Therapeutic+plasma+exchange&page=4",
    "query": {
      "intervention": "Therapeutic plasma exchange",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 87,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Therapeutic+plasma+exchange&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Therapeutic+plasma+exchange&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T18:30:42.400Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01035593",
      "title": "Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Rejection",
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "plasmapheresis and IVIG",
          "type": "PROCEDURE"
        },
        {
          "name": "recombinant C1 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-12",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-02-17",
      "last_synced_at": "2026-10-09T18:30:42.400Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01035593"
    },
    {
      "nct_id": "NCT00844844",
      "title": "Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atypical Hemolytic Uremic Syndrome"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 1,
      "start_date": "2009-05",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2015-07-23",
      "last_synced_at": "2026-10-09T18:30:42.400Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Grapevine",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00844844"
    },
    {
      "nct_id": "NCT04351438",
      "title": "Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Therapeutic Plasma Exchange",
        "Anticoagulant Therapy"
      ],
      "interventions": [
        {
          "name": "Active Comparator: centrifuge TPE with citrate",
          "type": "DEVICE"
        },
        {
          "name": "Active Comparator: Filter TPE with heparin",
          "type": "DEVICE"
        },
        {
          "name": "Active comparator: Filter TPE with citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "0 Years to 24 Years"
      },
      "enrollment_count": 108,
      "start_date": "2012-01-01",
      "completion_date": "2024-02-04",
      "has_results": false,
      "last_update_posted_date": "2024-02-08",
      "last_synced_at": "2026-10-09T18:30:42.400Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04351438"
    },
    {
      "nct_id": "NCT04374149",
      "title": "Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytokine Release Syndrome",
        "COVID19"
      ],
      "interventions": [
        {
          "name": "Therapeutic Plasma Exchange",
          "type": "PROCEDURE"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Prisma Health-Upstate",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-04-30",
      "completion_date": "2020-12-01",
      "has_results": true,
      "last_update_posted_date": "2021-12-02",
      "last_synced_at": "2026-10-09T18:30:42.400Z",
      "location_count": 1,
      "location_summary": "Greenville, South Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04374149"
    },
    {
      "nct_id": "NCT07674745",
      "title": "Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Therapeutic Plasma Exchange",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Intravenous immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Treatment as Usual",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 52,
      "start_date": "2026-10-01",
      "completion_date": "2031-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-09T18:30:42.400Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07674745"
    },
    {
      "nct_id": "NCT07756242",
      "title": "Pharmacokinetic Study of Therapeutic Plasma Exchange",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immune-related Adverse Event"
      ],
      "interventions": [
        {
          "name": "Spectra Optia Apheresis System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-11",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-09T18:30:42.400Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07756242"
    },
    {
      "nct_id": "NCT01556347",
      "title": "Multi-Drug Desensitization Protocol for Heart Transplant Candidates",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Transplantation"
      ],
      "interventions": [
        {
          "name": "Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "67 Years",
        "sex": "ALL",
        "summary": "18 Years to 67 Years"
      },
      "enrollment_count": 2,
      "start_date": "2012-07",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-10-09T18:30:42.400Z",
      "location_count": 1,
      "location_summary": "Spokane, Washington",
      "locations": [
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01556347"
    },
    {
      "nct_id": "NCT07543965",
      "title": "Cohort of Repeat Donor Experiences (CORE) Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Health Effects (Ferritin Levels, CRP Levels, iGg Levels, Self-reported Health)"
      ],
      "interventions": [
        {
          "name": "Plasmapheresis Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Westat",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 2090,
      "start_date": "2026-04-06",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-09T18:30:42.400Z",
      "location_count": 1,
      "location_summary": "Dallas, Georgia",
      "locations": [
        {
          "city": "Dallas",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07543965"
    },
    {
      "nct_id": "NCT05054894",
      "title": "Plasmapheresis for Treatment of Age-Related Frailty",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Age-Related Frailty"
      ],
      "interventions": [
        {
          "name": "Therapeutic Plasma Exchange (TPE)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Neurological Associates of West Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "50 Years to 95 Years"
      },
      "enrollment_count": 100,
      "start_date": "2021-03-19",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2022-04-18",
      "last_synced_at": "2026-10-09T18:30:42.400Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05054894"
    },
    {
      "nct_id": "NCT00029107",
      "title": "Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C",
        "Vasculitis"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 47,
      "start_date": "2001-12",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2012-04-16",
      "last_synced_at": "2026-10-09T18:30:42.400Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00029107"
    }
  ]
}